REFERENCES

Sequential Versus Concomitant Administration of Ribavirin and Interferon Alfa-n3 in Patients With Chronic Hepatitis C Not Responding to Interferon Alone: Results of a Randomized, Controlled Trial

1. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-356 [Medline].

2. Carreno V, Marriot E, Quiroga JA. Other approaches to the treatment of chronic viral hepatitis. J Hepatol 1993; 17(suppl. 1): 127-129 [Medline].

3. Marcellin P, Pouteau M, Boyer N, Castelnau C, Erlinger S, Benhamou JP. Retreatment with recombinant interferon-alfa in patients with chronic hepatitis C. J Infect Dis 1993; 167: 780-781 [Abstract].

4.National Institutes of Health Consensus Development Conference Panel Statement. Management of hepatitis C. HEPATOLOGY 1997; 26(suppl. 1): 25-105 [Medline].

5. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L. A pilot study of combination therapy with ribavirin plus interferon-alfa for interferon-alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812-817 [Medline].

6. Schvarcz R, Yun ZB, Sonnerborg A, Weiland O. Combined treatment with interferon-alfa-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol 1995; 46: 43-47 [Medline].

7. Brillanti S, Miglioli M, Barbara L. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J Hepatol 1995; 23(suppl. 2): 13-16 [Medline].

8. Scharvcz R, Ando Y, Sonnerborg A, Weiland O. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 1995; 23(suppl. 2): 17-21 [Medline].

9. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavalletto L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. J Hepatol 1997; 26: 961-966 [Medline].

10. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699 [Medline].

11. Shindo M, Di Bisceglie AM, Cheung L, Shih JWK, Cristiano K, Feinstone FM, Hoofnagle JH. Decrease in serum hepatitis C viral RNA during alpha-IFN therapy for chronic hepatitis C. Ann Intern Med 1991; 115: 700-704[Medline].

12. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337: 1058-1061.

13. Di Bisceglie AM, Shindo M, Fong T-L, Fried MW, Swain MG, Bergasa NV, Axiotis CA, et al. A pilot study of ribavirin therapy for chronic hepatitis C. HEPATOLOGY 1992; 16: 649-654 [Medline].

14. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25: 591-598.

15. Scotto G, Fazio V, Tantimonaco G. Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone. Ital J Gastroenterol 1996; 28: 505-511.

16. Andreone P, Cursaro C, Gramenzi A, Sbolli G, Fiorino S, Di Giammarino L, Miniero R, et al. IFN alfa-n3 vs IFN alfa-n3 plus ribavirin in chronic hepatitis C (CHC) resistant to other IFN alfa treatments:results of a randomized multicenter trial [Abstract]. HEPATOLOGY 1997; 26: 216A.

17. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naïve patients with chronic hepatitis C. J Hepatol 1995; 23(suppl. 2): 8-12.

18Koskinas J, Tibbs C, Saleh MG, Pereira LM, McFarlane IG, Williams R. Effects of ribavirin on intrahepatic and extrahepatic expression of hepatitis C virus in interferon nonresponsive patients. J Med Virol 1995; 45: 29-34.

19. Ning Q, Brown D, Parodo J, Cattral M, Fung L, Liu M, Rotstein O, et al. Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1 and procoagulant activity and preserves Th 1 cytokine production, but inhibits Th 2 cytokine response [Abstract]. HEPATOLOGY 1996; 24: 355A.

Return To Article

Copyright © 1998 by the American Association for the Study of Liver Diseases